These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 29739347)

  • 1. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
    Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V
    BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
    Banys-Paluchowski M; Witzel I; Riethdorf S; Pantel K; Rack B; Janni W; Fasching PA; Aktas B; Kasimir-Bauer S; Hartkopf A; Solomayer EF; Fehm T; Müller V
    Breast Cancer Res Treat; 2018 Nov; 172(1):93-104. PubMed ID: 30003393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.
    Banys-Paluchowski M; Witzel I; Aktas B; Fasching PA; Hartkopf A; Janni W; Kasimir-Bauer S; Pantel K; Schön G; Rack B; Riethdorf S; Solomayer EF; Fehm T; Müller V
    Sci Rep; 2019 Feb; 9(1):2318. PubMed ID: 30783124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
    Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
    Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
    Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Zeitz J; Pantel K; Fehm T;
    Breast Cancer Res; 2011 Jul; 13(4):R71. PubMed ID: 21745383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer.
    Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
    Sci Rep; 2017 Dec; 7(1):17307. PubMed ID: 29229933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
    Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
    Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T;
    Breast Cancer Res; 2012 Aug; 14(4):R118. PubMed ID: 22894854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.
    Bidard FC; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Cottu P; Beuzeboc P; Rolland E; Mathiot C; Pierga JY
    Breast Cancer Res; 2012 Feb; 14(1):R29. PubMed ID: 22330883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer.
    Janni WJ; Rack B; Terstappen LW; Pierga JY; Taran FA; Fehm T; Hall C; de Groot MR; Bidard FC; Friedl TW; Fasching PA; Brucker SY; Pantel K; Lucci A
    Clin Cancer Res; 2016 May; 22(10):2583-93. PubMed ID: 26733614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial.
    Riethdorf S; Müller V; Loibl S; Nekljudova V; Weber K; Huober J; Fehm T; Schrader I; Hilfrich J; Holms F; Tesch H; Schem C; von Minckwitz G; Untch M; Pantel K
    Clin Cancer Res; 2017 Sep; 23(18):5384-5393. PubMed ID: 28679772
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
    Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.
    Aurilio G; Sandri MT; Pruneri G; Zorzino L; Botteri E; Munzone E; Adamoli L; Facchi G; Cullurà D; Verri E; Rocca MC; Zurrida S; Iacovelli R; Nolè F
    Future Oncol; 2016 Sep; 12(17):2001-8. PubMed ID: 27255717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.